AMG334
Sponsors
Amgen, Novartis
Conditions
Episodic MigraineHeadache
Migraine
Phase 4
A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients
Active, not recruitingNL-OMON55516
Start: 2019-07-30Target: 30Updated: 2024-04-15
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
CompletedNCT03927144
Start: 2019-05-15End: 2022-09-30Updated: 2023-11-18